Pharmaceutical Executive
When people ask how health seekers look and act on the Web, there's no one answer: The online universe has become just as diverse as the rest of the world. Nowhere is this more evident than in the latest e-health statistics that, when taken together, paint a picture of customers who are beginning to find their feet-and new finesse-online.
When people ask how health seekers look and act on the Web, there's no one answer: The online universe has become just as diverse as the rest of the world. Nowhere is this more evident than in the latest e-health statistics that, when taken together, paint a picture of customers who are beginning to find their feet—and new finesse—online.
There are about 144 million online users, while 87 million are not online at all. The traditional drivers of health—income and education—remain strong predictors of online usage as well. Pharma is challenged to reach the less healthy, offline population. Some of these consumers may go online soon. Wal-Mart's debut last Christmas of the under-$500 PC, as well as increasing price competition among broadband providers, may bring greater numbers of less wealthy consumers online.
Patients say the Internet has become more credible. Search engines—in particular, Google—have helped raise credibility with technology that judges the value of the content by counting the number of links to a site.
The increase in broadband capabilities has brought about integration of online and TV content. And where the content goes, advertisers follow. Despite interest, many rich media initiatives remain in pilot testing, while the industry asks: Are people really watching this? The answer is yes, and those numbers will continue to grow.
Most product managers have a hard time believing that patients visit corporate Web sites. But as other Web sites guide millions of users to the corporate sites, companies have been left to wonder if they are doing everything they can. Patient resources, like Pfizerforliving.com, will likely play an increasingly important role in company branding.
European physicians spend less time with pharma's Web initiatives, which leaves local affiliates wrestling with basic questions, such as whether e-detailing works. However, doctors' lackluster attitude may have more to do with companies' low online investment and meager electronic resources.
These graphs offer insight into the strategic role of technology in marketing. The research is derived from telephone-based studies conducted by Manhattan Research with 4,031 US adults and 1,250 US physicians, except where otherwise noted.
After years of sharp increases, the number of consumers going online has slowed to single-digit growth—predictions are that five million or less will migrate online in the coming years. However, the number of consumers using the Internet to research health conditions and drugs still is growing rapidly. Expect a lot of that—and in particular, information found on pharma sites—to be driven by search engines and new media-enabled content that will capture more eyeballs and interest. Search engines are now driving significant numbers of consumers to corporate Web sites, which has industry asking questions about how best to use this tool.
Make no mistake, US physicians use and value the Internet more than their European counterparts—at least today. European companies are going through many of the same pilots that US companies undertook years back, and that may result in more online promotion, if done well. So far, companies in the United Kingdom and Germany are investing in these resources, while Spain, Italy, and France lag behind. In the United States, doctors respond well to e-initiatives and are also flocking to online physician-targeted portals for health information (with Merck-Medicus the only pharma-sponsored portal making the top six).
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.